药物洗脱支架：性价比高吗？ - Suppr | 超能文献

Drug-eluting stents: more dollars than sense?

作者信息

Garg Sunil, Eisenberg Mark J

出版信息

JACC Cardiovasc Interv. 2009 Dec;2(12):1188-9. doi: 10.1016/j.jcin.2009.11.001.

DOI:10.1016/j.jcin.2009.11.001

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Drug-eluting stents: more dollars than sense?药物洗脱支架：性价比高吗？

JACC Cardiovasc Interv. 2009 Dec;2(12):1188-9. doi: 10.1016/j.jcin.2009.11.001.

2

Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.第二代药物洗脱支架以及对快速可得的真实世界数据的持续需求。

JACC Cardiovasc Interv. 2009 Dec;2(12):1236-9. doi: 10.1016/j.jcin.2009.10.010.

3

Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).恩多雷药物洗脱支架与雷帕霉素洗脱依维莫司药物洗脱支架（Xience V）对比的 4 年临床与经济长期分析：来自 ENDEAVOR II 试验的结果（评价美敦力 AVE ABT-578 依维莫司洗脱驱动冠状动脉支架在初发原生冠状动脉病变中应用的安全性和有效性的随机对照试验）

JACC Cardiovasc Interv. 2009 Dec;2(12):1178-87. doi: 10.1016/j.jcin.2009.10.011.

4

Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.紫杉醇涂层球囊血管成形术和紫杉醇洗脱支架置入治疗稳定性冠心病患者冠状动脉支架内再狭窄的成本效果分析。

Clin Res Cardiol. 2012 Jul;101(7):573-84. doi: 10.1007/s00392-012-0428-2. Epub 2012 Feb 21.

5

Drug-eluting stents: safe but not sufficient.药物洗脱支架：安全但并不足够。

JACC Cardiovasc Interv. 2009 Jun;2(6):513-4. doi: 10.1016/j.jcin.2009.04.002.

6

Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).恩多雷佐塔鲁利姆洗脱支架与西罗莫司洗脱支架的长期临床和经济分析：来自 ENDEAVOR III 试验的 3 年结果（美敦力恩多雷药物[ABT-578]洗脱冠状动脉支架系统与西罗莫司洗脱冠状动脉支架系统在初发原生冠状动脉病变中的随机对照试验）。

JACC Cardiovasc Interv. 2009 Dec;2(12):1199-207. doi: 10.1016/j.jcin.2009.10.009.

7

Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data.采用当代数据更新的新型 Endeavor 支架治疗初发原生冠状动脉病变的成本效益分析。

EuroIntervention. 2010 Feb;5(7):826-32. doi: 10.4244/eijv5i7a138.

8

Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.随机比较口服雷帕霉素加裸金属支架与药物洗脱支架的节省成本和效果：来自阿根廷随机口服雷帕霉素（ORAR）III 试验的三年结果。

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.

9

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.会议报告：2007年9月27 - 28日于尼斯欧洲心脏之家举行的欧洲心脏病学会药物洗脱支架论坛

EuroIntervention. 2009 Jan;4(4):427-36.

10

Intravascular ultrasound optimization of drug-eluting stents: still not enough data.药物洗脱支架的血管内超声优化：数据仍不充足。

Catheter Cardiovasc Interv. 2010 Mar 1;75(4):584-5. doi: 10.1002/ccd.22488.

引用本文的文献

1

Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.外周动脉使用含紫杉醇器械后的死亡率：一项真实世界安全性分析。

Eur Heart J. 2020 Oct 7;41(38):3732-3739. doi: 10.1093/eurheartj/ehz698.

2

The impact of drug eluting stents availability on the treatment choice among medical therapy, percutaneous or surgical revascularisation and on 4-year clinical outcome in patients with coronary artery disease: a cohort study.药物洗脱支架的应用对冠心病患者药物治疗、经皮或手术血运重建治疗选择及 4 年临床结局的影响：一项队列研究。

BMJ Open. 2012 Oct 26;2(5). doi: 10.1136/bmjopen-2012-001926. Print 2012.